Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...

Ozempic, Wegovy and Mounjaro featured prominently. Known for their use in managing type 2 diabetes and aiding weight loss for ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed ...

Eli Lilly says Obstructive sleep apnea isn’t just an inconvenience, it’s a serious medical condition that impairs breathing and sleep quality. Obesity and obstructive sleep apnea are linked. People ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi received approval in January, the company ...

It is tailored to patients being treated with Lilly's oncology drugs – which ... than 30 DiGAs that have approved for use by the BfArM medical regulator and are covered by the national GKV ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity.